Clinical Trials Logo

Clinical Trial Summary

Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will have improved neurocognitive outcome at 22-26 months compared to placebo


Clinical Trial Description

Advances in neonatal care have led to significant improvements in the survival of the nearly 60,000 very low birth weight (VLBW) infants born each year in the U.S. Improving neurodevelopmental outcomes for these preterm infants continues to be a major goal for neonatal care providers. A subset of these infants sustain a grade 3 or 4 intraventricular hemorrhage (IVH) resulting in an increase in the incidence of developmental delay. Moreover, almost one third of preterm infants with normal head ultrasounds also develop cognitive delay. Although a variety of neuroprotective treatment strategies have been evaluated, no specific treatment has been identified to reduce or prevent brain injury in these most vulnerable preterm infants. A potential neuroprotective therapy involves administering erythropoiesis stimulating agents (ESAs) such as erythropoietin (Epo) and Darbepoetin (Darbe, a longer acting ESA). In addition to stimulating erythropoiesis, ESAs have been shown to be protective in the developing brain in animal models, making it possibly beneficial for very premature infants who are at risk for intraventricular hemorrhage, hypoxic-ischemic injury, and developmental delay. The neuroprotective mechanisms of ESAs include increased neurogenesis, decreased neuronal susceptibility to glutamate toxicity, decreased neuronal apoptosis, decreased inflammation, decreased nitric oxide-mediated injury, increased antioxidant response, decreased axonal degeneration, and increased protective effects on glia. This is a randomized, masked, placebo controlled clinical study in which enrolled infants will receive weekly Darbe or placebo (sham) dosing. Extended follow-up: Subjects will be seen for follow-up at 4-5 years (i.e., 4 years - 4 years 11 months) corrected age and 6-7 years (i.e., 6 years - 6 years 11 months) corrected age to characterize the functional, behavioral and neurological outcomes of the extremely low birth weight (ELBW) population at school age based on treatment with darbepoetin versus placebo in the neonatal period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03169881
Study type Interventional
Source NICHD Neonatal Research Network
Contact
Status Active, not recruiting
Phase Phase 3
Start date September 20, 2017
Completion date August 2028

See also
  Status Clinical Trial Phase
Completed NCT04523441 - Early Support and Physiotherapy for Children and Their Motor Skills
Completed NCT05828420 - The Effect of Music, White Noise and Heart Sound on Neonatal Pain N/A
Completed NCT03272594 - The Influence of Breastfeeding on Cortical Activity During Procedures Phase 3
Recruiting NCT06344741 - Consequences of Admission to the Delivery Room in the Early and Late Phases
Completed NCT05036915 - The Effect of Routine and Random Pacifier Use Methods in Preterm Infants N/A
Recruiting NCT05223790 - Assessment of the NIPE in Very Premature Infant Ventilated and Sedated in Neonatal Reanimation.
Completed NCT05221463 - The Effect of Video-assisted Breastfeeding Education Given to Mothers of Hospitalized Newborns on Breastfeeding N/A
Completed NCT04354467 - Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict AKI in the NICU
Active, not recruiting NCT02545712 - Safe Excipient Exposure in Neonates and Small ChildreN N/A
Not yet recruiting NCT05451875 - Comparison of Continuous Non-invasive All Vital Signs Monitoring Devices With Invasive Gold Standard for Children
Active, not recruiting NCT04295564 - Extending CPAP Therapy in Stable Preterm Infants to Increase Lung Growth and Function Phase 2/Phase 3
Withdrawn NCT02764528 - Intervention Study to Improve Maternal Handwashing N/A
Completed NCT02379936 - Evaluation of Lactate Dehydrogenase as Decision Support for Admissions to Neonatal Ward N/A
Active, not recruiting NCT04545866 - The Budesonide in Babies (BiB) Trial Phase 3